Sun Pharmaceutical Industries Limited (BOM:524715)
1,885.10
-17.90 (-0.94%)
At close: Nov 20, 2026
Sun Pharmaceutical Industries Employees
Sun Pharmaceutical Industries had 47,000 employees as of March 31, 2026. The number of employees increased by 4,000 or 9.30% compared to the previous year.
Employees
47,000
Change (1Y)
4,000
Growth (1Y)
9.30%
Revenue / Employee
13.11M INR
Profits / Employee
2.33M INR
Market Cap
4.52T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 47,000 | 4,000 | 9.30% |
| Mar 31, 2025 | 43,000 | 0 | - |
| Mar 31, 2024 | 43,000 | 2,000 | 4.88% |
| Mar 31, 2023 | 41,000 | 3,000 | 7.89% |
| Mar 31, 2022 | 38,000 | 1,000 | 2.70% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 47,000 |
| Cipla | 31,369 |
| Zydus Lifesciences | 29,980 |
| Aurobindo Pharma | 29,209 |
| Mankind Pharma | 20,451 |
| Alkem Laboratories | 19,346 |
| Ipca Laboratories | 17,210 |
| Glenmark Pharmaceuticals | 16,946 |
Sun Pharmaceutical Industries News
- 23 days ago - Sun Pharmaceutical Industries Transcript: Q2 26/27 - Transcripts
- 23 days ago - Sun Pharmaceutical Industries Quarterly report: Q2 2027 - Filings
- 23 days ago - Sun Pharmaceutical Industries Slides: Q2 2027 - Filings
- 23 days ago - India orders Sun Pharma to halt eye-care drug production at plant after quality lapses - Reuters
- 23 days ago - Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong - Reuters
- 23 days ago - Sun Pharma's Ilumya Wins FDA Approval For Active Psoriatic Arthritis - Nasdaq
- 4 weeks ago - Sun Pharma Reports Durable UNLOXCYT Responses In Advanced Skin Cancer - Nasdaq
- 4 weeks ago - Sun Pharma's UNLOXCYT Added As NCCN Category 2A Option For Locally Advanced Skin Cancer - Nasdaq